Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCC
- Status
- RECRUITING
- Phase
- PHASE2
Clinical Trials Related to Durvalumab
Related studies linked through entity extraction aliases.
Immunotherapy, Hormone Therapy, and AKT Inhibitor for Premenopausal ER Positive MBC
- Status
- RECRUITING
- Phase
- PHASE2
Brigatinib Post Definitive Chemo-radiotherapy in Patients with ALK-fusion Non-small Cell Lung Cancer
- Status
- WITHDRAWN
- Phase
- PHASE2
Organ Preservation With Durvalumab-based Immunotherapy in Combination With Chemoradiation as Definitive Therapy for Early Stage Esophageal Adenocarcinoma With Indication for Radical Surgery
- Status
- RECRUITING
- Phase
- PHASE2
A Study of LSTA1 When Added to Standard of Care Versus Standard of Care Alone in Patients With Advanced Solid Tumors
- Status
- TERMINATED
- Phase
- PHASE2
SIRT With Tremelimumab and Durvalumab for Resectable HCC
- Status
- RECRUITING
- Phase
- PHASE1
Quick Start Durvalumab Following Chemoradiation for Stage III Nonsmall Cell Lung Cancer
- Status
- RECRUITING
- Phase
- PHASE2
Phase III, Open-label, First-line Study of Dato-DXd in Combination With Durvalumab and Carboplatin for Advanced NSCLC Without Actionable Genomic Alterations
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
A French Real-life Study: EvaluatioN of durvALumab Utilization and Effectiveness for First Line Extensive Stage Small Cell Lung Cancer.
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- N/A
Durvalumab Combined With GemCis Neoadjuvant Therapy of Resectable Intrahepatic Cholangiocarcinoma With High Recurrence Risk
- Status
- RECRUITING
- Phase
- PHASE2
Y-90 With Durvalumab/Gem/Cis in Intrahepatic Cholangio
- Status
- RECRUITING
- Phase
- PHASE2
Durvalumab Combined With Chemotherapy Neoadjuvant Therapy of Biliary Tract Cancer
- Status
- UNKNOWN
- Phase
- PHASE2
REStoring lymphoCytes Using NKTR-255* After chemoradiothErapy in Solid Tumors (RESCUE)
- Status
- RECRUITING
- Phase
- PHASE2
A Study of Dato-DXd With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy (TROPION-Breast03)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer
- Status
- RECRUITING
- Phase
- PHASE3
Ph2 Study of Savolitinib and Durvalumab (MEDI4736) Combination in Advanced MET Amplified Gastric Cancer(VIKTORY-2)
- Status
- RECRUITING
- Phase
- PHASE2
Durvalumab Maintenance After Thoracic Chemoradiotherapy in Frail Small Cell Lung Cancer Patients Whose Disease is Limited to the Thorax
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Restoring Sensitivity To Immunotherapy In Advanced Triple Negative Breast Cancer Exploiting Ceralasertib Priming Followed By Combined Durvalumab/Nab-Paclitaxel
- Status
- RECRUITING
- Phase
- PHASE2
Randomized Trial Comparing Standard of Care Versus Immune- Based Combination in Relapsed Stage III Non-small-cell Lung Cancer (NSCLC) Pretreated With Chemoradiotherapy and Durvalumab
- Status
- RECRUITING
- Phase
- PHASE2
Study of Durvalumab Plus Tremelimumab as First-line Treatment in Chinese Patients With Unresectable Hepatocellular Carinoma
- Status
- RECRUITING
- Phase
- PHASE3